![Parisa Zamiri](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Parisa Zamiri is currently the Chief Medical Officer at Opthea Ltd. She previously held positions as the Director-Pre-Clinical Sciences at Arsenal Medical, Inc. from 2007 to 2011, the Chief Medical Officer at Graybug Vision, Inc. from 2020 to 2023, and the VP & Global Head-Clinical Development at Novartis AG from 2012 to 2020.
She also served as the Chief Medical Officer at CalciMedica, Inc. and Complement Therapeutics Ltd. Dr. Zamiri holds a doctorate degree from University College London and a graduate degree from King's College London.
Anciens postes connus de Parisa Zamiri
| Sociétés | Poste | Fin |
|---|---|---|
| OPTHEA LIMITED | Directeur Technique/Scientifique/R&D | 15/07/2025 |
| CALCIMEDICA, INC. | Directeur Technique/Scientifique/R&D | 28/02/2023 |
| CALCIMEDICA, INC. | Directeur Technique/Scientifique/R&D | 28/02/2023 |
| NOVARTIS AG | Corporate Officer/Principal | 01/06/2020 |
Arsenal Medical, Inc.
 Arsenal Medical, Inc. Medical SpecialtiesHealth Technology Develops biomaterials provides local therapy for important medical conditions across therapeutic areas | Corporate Officer/Principal | 01/11/2011 |
Formation de Parisa Zamiri
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
52
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Arsenal Medical, Inc.
Arsenal Medical, Inc. Medical SpecialtiesHealth Technology Develops biomaterials provides local therapy for important medical conditions across therapeutic areas | Health Technology |
Graybug Vision, Inc.
 Graybug Vision, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company, which focuses on developing transformative medicines for the treatment of chronic diseases of retina and optic nerve | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Opthea Ltd.
 Opthea Ltd. BiotechnologyHealth Technology Operates as a biotechnology company that develops novel therapies for treatment retinal diseases | Health Technology |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Complement Therapeutics Ltd.
 Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops complement medicines | Health Technology |
CalciMedica, Inc.
 CalciMedica, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
